

Efficacy of Magnesium Sulfate in Addition to Melatonin Therapy in Neonates With Hypoxic-Ischemic Encephalopathy

Review began 12/16/2021
Review ended 01/09/2022
Published 01/12/2022

© Copyright 2022

Khan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Muhammad H. Khan¹, Qurrat-ul Ann¹, Muhammad S. Khan², Nadeem Ahmad¹, Moiz Ahmed³

1. Department of Neonatology, Pakistan Institute of Medical Sciences, Islamabad, PAK 2. Department of Neonatology, Pakistan Atomic Energy Commission General Hospital, Islamabad, PAK 3. Department of Neonatology, Jinnah Postgraduate Medical Centre, Karachi, PAK

Corresponding author: Muhammad H. Khan, drhayatbangash@gmail.com

Abstract

Background: One of the most important causes of neonatal deaths in developing nations is birth asphyxia. Though the probability of a complete recovery is very low, hypoxic-ischemic encephalopathy (HIE) associated with asphyxia can be managed with multiple treatment options. The study evaluated the efficacy of the addition of magnesium sulfate (MgSO_4) to melatonin therapy in neonates with HIE.

Methodology: A prospective, observational study was conducted in the department of neonatal intensive care, Pakistan Institute of Medical Sciences Hospital, Islamabad, Pakistan from October 2020 to March 2021. All neonates with an Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) score of less than five at five minutes, umbilical blood pH of less than 7.0, and moderate neonatal encephalopathy as detected on the modified Sarnat score which is a clinical tool used for the assessment of the severity of HIE were included in the study. Neonates with congenital abnormalities, intrauterine growth retardation, neonatal sepsis, and infants born to mothers with diabetes mellitus type 2 were excluded from the study. The infants were randomly assigned to either of the groups, i.e., i) group 1 included neonates who were administered at least three doses of magnesium sulfate (MgSO_4) infusion in addition to melatonin, or ii) group 2 included neonates who were administered melatonin only. Blood samples of all neonates were evaluated and compared between the two groups.

Results: A total of 90 neonates with HIE were included in the study. There was a predominance of female neonates. The mean ages of babies in group 1 and group 2 were 37.2 ± 0.43 and 37.3 ± 0.59 weeks, respectively. The mean weight on the term was 2.88 ± 0.11 and 2.89 ± 0.10 , respectively. The Apgar score at 5 mins in group 1 was 1.73 ± 0.81 while in group 2, 1.82 ± 0.94 . It was found that there was a more significant improvement in pH after 3 days and after one week of treatment in group 1 as compared to group 2. The mean pH in babies after three days of intervention was 7.23 ± 0.03 in group 1 which was significantly better than group 2 ($p < 0.0001$). After seven days, the mean normalized to 7.39 ± 0.04 in group 1 ($p < 0.0001$). It was found that in patients in group 1, the mortality was lower than in group 2 ($p < 0.0001$).

Conclusion: HIE patients who were administered melatonin in combination with magnesium sulfate yielded better patient outcomes. Thus, it was concluded that the use of magnesium sulfate as dual therapy with melatonin improved patient outcomes for HIE. However, it is recommended that similar studies are conducted with a wider range of parameters, such as duration of hospital stay and assessment of the neurological outcomes of the patients.

Categories: Internal Medicine, Pediatrics

Keywords: neonates, mgso4, melatonin, magnesium sulfate, hie, hypoxic-ischemic encephalopathy

Introduction

The World Health Organization indicated that about 16,000 children under the age of five die per day. The most frequent causes of child mortality are infectious diseases, preterm, and intrapartum-associated complications [1]. In third world countries, a major cause of childhood mortality is hypoxic-ischemic encephalopathy (HIE), with the incidence of asphyxia ten times higher than that in more developed countries [2].

Melatonin, chemically N-acetyl-5-methoxytryptamine, is a hormone released by the pineal gland and is considered to have multiple functions in the human body. Melatonin plays an active role in the maintenance of physiological functions such as regulating the circadian rhythm, contributing to reproductive, cerebrovascular neuroendocrine, and neuroimmunological activities along with its effect as an anti-inflammatory and an antioxidant [3-5]. Through its receptor and non-receptor actions, melatonin plays a crucial role as an antiapoptotic and anti-excitotoxic, thereby serving as a potent neuroprotector. Melatonin

How to cite this article

Khan M H, Ann Q, Khan S, et al. (January 12, 2022) Efficacy of Magnesium Sulfate in Addition to Melatonin Therapy in Neonates With Hypoxic-Ischemic Encephalopathy. Cureus 14(1): e21163. DOI 10.7759/cureus.21163

reduces the formation of proinflammatory molecules and inhibits cyclooxygenase activity, and is thus considered as an immune modulator [5].

Recent studies have also revealed that melatonin serves as a regulator of the blood-brain barrier, nitric oxide synthase, and various other antioxidant enzymes. The anti-apoptotic activity of melatonin markedly reduces the formation of proapoptotic substances thus maintaining mitochondrial permeability [6]. The analgesic effects of melatonin are also well known and are used in minor procedures to avoid procedural pain as it diminishes the release of proinflammatory cytokines in babies born preterm, who are suffering from respiratory distress, or infants with bacterial septicemia [7].

In the year 2001, Fulia et al. revealed that there was a significant reduction in levels of MDA and nitrates in the serum of asphyxiated newborn children, which was associated with melatonin administration in the first 6 hours after birth [8]. However, not enough clinical trials have been conducted with a large sample size to ascertain the effects and benefits of melatonin in the management of children with HIE. At present, hypothermia is considered to be the single most appropriate treatment for the management of HIE in neonates. Recently, many studies have been evaluating the association between hypothermia and melatonin in conjunction with magnesium sulfate (MgSO_4) infusion use to enhance the neuroprotective effect of the brain and improve patient outcomes [9,10]. Thus, the present study aimed at evaluating the effectiveness of melatonin administration in addition to MgSO_4 in improving patient outcomes.

Materials And Methods

A prospective, observational study was conducted in the department of neonatal intensive care, Pakistan Institute of Medical Sciences Hospital, Islamabad, Pakistan, from October 2020 to March 2021. The study was conducted after the ethical approval from the institutional review board was procured (Reference # IRB/P-54564/PIMS). Informed verbal and written consent was obtained from the parents of the neonates recruited in the study. A non-probability convenience sampling technique was employed for the recruitment of the participants.

All neonates with an Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) score of less than 5 at 5 minutes, umbilical blood pH of less than 7.0, and moderate neonatal encephalopathy as detected on the modified Sarnat score which is a clinical tool used for the assessment of the severity of HIE were included in the study. Neonates with congenital abnormalities, intrauterine growth retardation, neonatal sepsis, and infants born to mothers with diabetes mellitus type II were excluded from the study.

A total of 90 neonates with HIE were included in the study. They were randomly assigned to either of the groups, i.e., i) group 1 included neonates who were administered at least three doses of magnesium sulfate (MgSO_4) infusion (250 mg/kg per day intravenous over 60 minutes at days 0, 1, and 3 in addition to five doses of melatonin (10 mg/kg daily enteral for five consecutive days), or ii) group 2 included neonates who were administered the similar dose of melatonin only.

Blood samples were collected by a trained nurse from all neonates at presentation, on day 3, and on day 7. Complete blood count, serum electrolytes including serum magnesium concentrations, and arterial blood gases were assessed. Arterial blood pressure was regularly documented. All neonates were divided into groups according to the blood pressure categories. Normal arterial blood pressure in neonates was set as (40-65) mmHg whereas hypotension was considered at levels below 40 mmHg. Throughout the study, the patients were strictly monitored for any adverse outcomes or side effects such as respiratory depression or hypotension.

SPSS version 25 (IBM Corp., Armonk, NY) was used to run data analysis. Comparison between the two studied groups was done using the chi-square test and student t-tests to find out the associations between the dependent and the independent variables. A p-value equal to or less than 0.05 was considered statistically significant.

Results

The baseline patient characteristics are provided in Table 1. The study showed a predominance of female neonates. The mean ages of babies in group 1 and group 2 were 37.2 ± 0.43 and 37.3 ± 0.59 weeks, respectively. The mean weight on the term was 2.88 ± 0.11 and 2.89 ± 0.10 , respectively. The APGAR score at 5 min in group 1 was 1.73 ± 0.81 while in group 2, 1.82 ± 0.94 (Table 1).

Parameter	Group 1	Group 2	P-value
Sex			0.421
Male	14 (31.1%)	18 (40%)	
Female	32 (71.1%)	27 (60%)	
Gestational age (wks)			0.982
Range	36-38	36-38	
Mean \pm SD	37.2 \pm 0.43	37.3 \pm 0.59	
Median	37	37	
Weight (Kg)			0.979
Range	2.67-3.0	2.65-2.98	
Mean \pm SD	2.88 \pm 0.11	2.89 \pm 0.10	
Median	2.95	2.96	
Apgar score at 5 min			0.861
Range	1.0-3.0	1.0-3.0	
Mean \pm SD	1.73 \pm 0.81	1.82 \pm 0.94	
Median	1.6	1.4	
Apgar score at 10 min			0.61
Range	2.0-5.0	2.0-5.0	
Mean \pm SD	3.41 \pm 1.3	3.49 \pm 1.2	
Median	3.5	3.66	

TABLE 1: Comparison between the two studied groups according to demographic data and APGAR scores

APGAR - Appearance, Pulse, Grimace, Activity, and Respiration

Table 2 compared the parameters after treatment with magnesium sulfate (MgSO_4) in addition to melatonin (group 1) versus group 2 (melatonin only). It was found that there was a more significant improvement in pH after three days and after one week of treatment in group 1 as compared to group 2. The mean pH in babies after three days of intervention was 7.23 ± 0.03 in group 1, which was significantly better than group 2 ($p < 0.0001$). After seven days, the mean normalized to 7.39 ± 0.04 in group 1 ($p < 0.0001$) (Table 2).

Parameter	Group 1	Group 2	P-value
Before MgSO ₄ infusion (at enrollment)			0.281
Range	7.03-7.14	7.05-7.17	
Mean ± SD	7.07 ± 0.02	7.08 ± 0.04	
Median	7.06	7.07	
After 3 days			<0.0001
Range	7.20-7.31	7.15-7.24	
Mean ± SD	7.23 ± 0.03	7.17 ± 0.05	
Median	7.22	7.18	
After 7 days			<0.0001
Range	7.32-7.44	7.16-7.28	
Mean ± SD	7.39 ± 0.04	7.2 ± 0.03	
Median	7.38	7.22	

TABLE 2: Comparison between the two studied groups according to pH

MgSO₄: magnesium sulfate

Upon assessing the magnesium levels in each group, it was found that the difference was significant. At baseline, the mean magnesium levels were 1.71 ± 0.12 and 1.75 ± 0.09 in group 1 and group 2, respectively. However, in three days of infusion, the levels rose to 2.3 ± 0.10 and 1.99 ± 0.09 , respectively ($p < 0.0001$). Similarly, by the seventh day of treatment, the magnesium levels in group 1 versus group 2 were 2.39 ± 0.10 and 2.14 ± 0.07 , respectively (Table 3).

Parameter	Group 1	Group 2	P-value
Before MgSO ₄ infusion (at enrollment)			0.299
Range	1.60-1.90	1.60-1.90	
Mean ± SD	1.71 ± 0.12	1.75 ± 0.09	
Median	1.79	1.77	
After 3 days			<0.0001
Range	2.10-2.40	1.85-2.05	
Mean ± SD	2.3 ± 0.10	1.99 ± 0.09	
Median	2.24	1.91	
After 7 days			<0.0001
Range	2.33-2.50	2.10-2.25	
Mean ± SD	2.39 ± 0.10	2.14 ± 0.07	
Median	2.41	2.15	

TABLE 3: Comparison between the two studied groups according to serum magnesium level in mg/L

MgSO₄: magnesium sulfate

Table 4 shows the comparison of adverse effects in both groups. It was found that in patients in group 1, the mortality was lower than in group 2 ($p < 0.0001$) (Table 4).

Parameter	Group 1 (n=45)	Group 2 (n=45)	P-value
Deaths	29 (64.4%)	39 (86.7%)	0.014
Seizure	28 (62.2%)	25 (55.6%)	0.52
Thrombocytopenia	34 (75.6%)	28 (62.2%)	0.172
Renal failure	20 (44.4%)	20 (44.4%)	0.832
Hypotension			0.483
Severe	19 (42.2%)	22 (48.9%)	
Mild to moderate	19 (42.2%)	17 (37.8%)	
Total	37 (82.2%)	39 (86.7%)	
Intracranial hemorrhage			0.153
< grade 3	43 (95.56%)	45 (100%)	
>= grade 3	2 (4.44%)	0 (0%)	
Total	45 (100%)	45 (100%)	

TABLE 4: Comparison of distribution of adverse outcomes between the two groups

Discussion

HIE among neonates causes damage to neurons and white matter, resulting in a significant rise in neonatal mortality [10]. Neurological injury in these cases occurs due to a lack of mitochondrial energy and a much higher expression of excitatory neurotransmitters in neonates [11].

The current study analyzed the efficacy of melatonin and magnesium sulfate (MgSO₄) in the management of HIE among neonates. The results showed that both study groups had a lower pH which was indicative of acidosis. Low magnesium levels were also noted in both groups prior to the administration of MgSO₄. However, after MgSO₄ infusion, group 1 showed improved levels of magnesium on day two and day six while group 2 showed a very slight rise in magnesium levels. Improvements were more distinctively seen among patients of group 1, who were treated with MgSO₄ in addition to melatonin.

A randomized controlled trial that evaluated the efficacy of melatonin in the management of infants with HIE revealed that patients suffered from fewer episodes of seizures and showed minimal signs of white matter injury on MRI, with much lower morbidity and mortality rates following treatment with melatonin [12]. These findings were consistent with our results, which also showed a slight improvement in patient condition following monotherapy with melatonin, even though much better results were seen in patients on dual therapy.

Our findings revealed that patients given melatonin in combination with MgSO₄ yielded better patient outcomes. The role of MgSO₄ in HIE was evaluated by Tagin et al., who reported that MgSO₄ was associated with significant improvement in patient well-being and had no side effects [13]. Another study by Siddiqui et al. also reported similar results and revealed that MgSO₄ played a role in improving neonatal reflexes and reducing the duration of seizures without any side effects [14].

The results of our study were inconsistent with those of Galinsky et al., who reported that MgSO₄ led to no improvement in the neurological symptoms of the patient, with an absence of association between MgSO₄ and improved outcomes among children at school-going age [15]. A similar study also revealed conflicting results and reported a lack of neurological impact of MgSO₄ in cases of HIE [16]. This implies that though MgSO₄ shows significant clinical results in neonates and infants, it does not improve outcomes of children belonging to the school-going age group. This indicates that the long-term benefits of MgSO₄ may be minimal in improving neurodevelopmental outcomes [17].

The results of the current study were limited by the small sample size and the lack of follow-up by patients, which made it difficult to assess the neurodevelopmental outcomes of the babies belonging to both groups. Further studies are recommended to ascertain these findings in our population which is a resource-restrained region.

Conclusions

Our findings revealed that patients given melatonin in combination with magnesium sulfate yielded better patient outcomes. Thus, it was concluded in the study that the use of magnesium sulfate as dual therapy with melatonin improved patient outcomes for HIE. However, it is recommended that similar studies are conducted with a wider range of parameters, such as duration of hospital stay and assessment of the neurological outcomes of the patients.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Pakistan Institute of Medical Sciences issued approval IRB/P-54564/PIMS. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Colella M, Biran V, Baud O: Melatonin and the newborn brain. *Early Hum Dev.* 2016, 102:1-3. [10.1016/j.earlhumdev.2016.09.001](https://doi.org/10.1016/j.earlhumdev.2016.09.001)
2. Vannucci RC: Hypoxic-ischemic encephalopathy. *Am J Perinatol.* 2000, 17:113-20. [10.1055/s-2000-9293](https://doi.org/10.1055/s-2000-9293)
3. Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ: Melatonin, energy metabolism, and obesity: a review. *J Pineal Res.* 2014, 56:371-81. [10.1111/jpi.12137](https://doi.org/10.1111/jpi.12137)
4. Jan JE, Reiter RJ, Wasdell MB, Bax M: The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. *J Pineal Res.* 2009, 46:1-7. [10.1111/j.1600-079X.2008.00628.x](https://doi.org/10.1111/j.1600-079X.2008.00628.x)
5. Goswami N, Abulafia C, Vigo D, Moser M, Cornelissen G, Cardinali D: Falls risk, circadian rhythms and melatonin: current perspectives. *Clin Interv Aging.* 2020, 15:2165-74. [10.2147/CIA.S283342](https://doi.org/10.2147/CIA.S283342)
6. Acuna-Castroviejo D, Escames G, Rodriguez MI, Lopez LC: Melatonin role in the mitochondrial function. *Front Biosci.* 2007, 12:947-63. [10.2741/2116](https://doi.org/10.2741/2116)
7. Gopagondanahalli KR, Li J, Fahey MC, Hunt RW, Jenkin G, Miller SL, Malhotra A: Preterm hypoxic-ischemic encephalopathy. *Front Pediatr.* 2016, 4:114. [10.3389/fped.2016.00114](https://doi.org/10.3389/fped.2016.00114)
8. Fulia F, Gitto E, Cuzzocrea S, et al.: Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. *J Pineal Res.* 2001, 31:343-9. [10.1034/j.1600-079x.2001.310409.x](https://doi.org/10.1034/j.1600-079x.2001.310409.x)
9. Chakkarapani AA, Aly H, Benders M, et al.: Therapies for neonatal encephalopathy: targeting the latent, secondary and tertiary phases of evolving brain injury. *Semin Fetal Neonatal Med.* 2021, 26:101256. [10.1016/j.siny.2021.101256](https://doi.org/10.1016/j.siny.2021.101256)
10. Dixon BJ, Reis C, Ho WM, Tang J, Zhang JH: Neuroprotective strategies after neonatal hypoxic ischemic encephalopathy. *Int J Mol Sci.* 2015, 16:22368-401. [10.3390/ijms160922368](https://doi.org/10.3390/ijms160922368)
11. Yıldız EP, Ekici B, Tatlı B: Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. *Expert Rev Neurother.* 2017, 17:449-59. [10.1080/14737175.2017.1259567](https://doi.org/10.1080/14737175.2017.1259567)
12. Aly H, Elmahdy H, El-Dib M, et al.: Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. *J Perinatol.* 2015, 35:186-91. [10.1038/jp.2014.186](https://doi.org/10.1038/jp.2014.186)
13. Tagin M, Shah PS, Lee KS: Magnesium for newborns with hypoxic-ischemic encephalopathy: a systematic review and meta-analysis. *J Perinatol.* 2013, 33:663-9. [10.1038/jp.2013.65](https://doi.org/10.1038/jp.2013.65)
14. Siddiqui MA, Butt TK: Role of intravenous magnesium sulphate in term neonates with hypoxic ischemic encephalopathy (HIE) in a low-income country: a randomised clinical trial. *J Coll Physicians Surg Pak.* 2021, 30:817-20. [10.29271/jcsp.2021.07.817](https://doi.org/10.29271/jcsp.2021.07.817)
15. Galinsky R, Dean JM, Lingam I, Robertson NJ, Mallard C, Bennet L, Gunn AJ: A systematic review of magnesium sulfate for perinatal neuroprotection: what have we learnt from the past decade?. *Front Neurol.* 2020, 11:449. [10.3389/fneur.2020.00449](https://doi.org/10.3389/fneur.2020.00449)
16. Lingam I, Robertson NJ: Magnesium as a neuroprotective agent: a review of its use in the fetus, term infant with neonatal encephalopathy, and the adult stroke patient. *Dev Neurosci.* 2018, 40:1-12. [10.1159/000484891](https://doi.org/10.1159/000484891)
17. Doyle LW, Anderson PJ, Haslam R, Lee KJ, Crowther C: School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. *JAMA.* 2014, 312:1105-13. [10.1001/jama.2014.11189](https://doi.org/10.1001/jama.2014.11189)